Evofem Biosciences, Inc.

We are a San Diego-based commercial-stage biopharmaceutical company focused on commercializing products for women's sexual and reproductive health. Our first commercial product, PHEXX®, was approved by the FDA on May 22, 2020, for pregnancy prevention and launched in the U.S. in September 2020. PHEXX is a non-hormonal prescription contraceptive vaginal gel, used 0-60 minutes before intercourse. It is hormone-free and non-systemic, avoiding side effects associated with hormonal methods such as depression, weight gain, headaches, loss of libido, mood swings, and irritability. Hormonal contraceptives may not be suitable for women with certain medical conditions, including clotting disorders, hormone-sensitive cancers, diabetes, or a BMI over 30, as well as those who are breastfeeding or smoke. According to the National Center for Health Statistics, approximately 15.9 million women in the U.S. do not wish to become pregnant and will not use a hormonal contraceptive, based on 2022-2023 data. We acquired global rights to SOLOSEC® on July 14, 2024, and relaunched it in November 2024. SOLOSEC is an FDA-approved single-dose oral antimicrobial for treating bacterial vaginosis (BV) and trichomoniasis. Outside the U.S., we commercialize our products through partnerships and/or license agreements.